Divi's Laboratories Limited (NSE:DIVISLAB)
5,757.05
-221.25 (-3.70%)
Feb 21, 2025, 3:29 PM IST
Divi's Laboratories Revenue
Divi's Laboratories had revenue of 23.19B INR in the quarter ending December 31, 2024, with 25.01% growth. This brings the company's revenue in the last twelve months to 90.78B, up 21.16% year-over-year. In the fiscal year ending March 31, 2024, Divi's Laboratories had annual revenue of 78.45B with 1.00% growth.
Revenue (ttm)
90.78B
Revenue Growth
+21.16%
P/S Ratio
16.84
Revenue / Employee
9.32M
Employees
9,741
Market Cap
1,528.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 78.45B | 780.00M | 1.00% |
Mar 31, 2023 | 77.67B | -11.93B | -13.31% |
Mar 31, 2022 | 89.60B | 19.90B | 28.56% |
Mar 31, 2021 | 69.69B | 15.75B | 29.20% |
Mar 31, 2020 | 53.94B | 4.48B | 9.06% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Fortis Healthcare | 75.61B |
Divi's Laboratories News
- 13 days ago - Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - GuruFocus
- 13 days ago - Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 18 days ago - Divi’s Labs remains our top pick, target price at Rs 6,850 after Q3 results: Citi - Business Upturn
- 2 months ago - Citi reaffirms ‘Buy’ on Divi’s Laboratories, sees buying opportunities amid BioSecure delays - Business Upturn
- 3 months ago - Divi's Laboratories Ltd (BOM:532488) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst ... - GuruFocus
- 3 months ago - Q2 2025 Divi's Laboratories Ltd Earnings Call Transcript - GuruFocus
- 4 months ago - Divis Labs surges over 4.5% on positive brokerage report - Business Upturn
- 4 months ago - Citi initiates Buy on Divis Lab, sees 15% upside in share price - Business Upturn